Business Standard

Thursday, January 23, 2025 | 11:42 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Biocon targets $200 mn revenue from biosimilars on the back of EMs growth

The approval of Biocon's biosimilar insulin Glargine in about 25 countries will be a revenue-driving force

Employees of Biocon Ltd work inside the company's research and development centre in Bengaluru. File photo: Reuters
Premium

Employees of Biocon Ltd work inside the company's research and development centre in Bengaluru. File photo: Reuters

Samreen Ahmad Bengaluru
Biotechnology major Biocon is aiming to register a 66 per cent growth in its biologics business this fiscal, which the company hopes will help it clock a revenue of $200 million on the back of emerging markets growth.

Its current revenue from the biosimilars market is around $120 million. In the last six months, the company (along with its partner Mylan) has made significant progress on the regulatory front in the US and EU markets and has built a biosimilars pipeline. However, it is still some time away for these markets to drive growth. The company feels that developed markets would

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in